ArticleBehavioral neuroscience2011
The risky business of dopamine agonists in Parkinson disease and impulse control disorders.
Article in Behavioral neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 104 citations in OpenAlex.
- Trial
- The Influence of Bilateral Subthalamic Nucleus Deep Brain Stimulation on Impulsivity and Prepulse Inhibition in Parkinson's Disease Patients.Stereotactic and functional neurosurgery · 2015Trial
- Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease.Journal of cognitive neuroscience · 2012Trial
- Microstimulation of the human dopaminergic midbrain enhances outcome-related happiness and reduces loss seeking.bioRxiv : the preprint server for biology · 2026Article
- Sensitivity to negative-feedback processing in people with Parkinson's disease and impulsive-compulsive behaviours.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Sense of agency and decision making.Frontiers in psychology · 2026Article
- Neuropsychological insights into creativity in people with Parkinson's disease.NPJ Parkinson's disease · 2025Article
- The Cognitive Cost of Motor Control: A Systematic Review and Meta-Analysis of Parkinson's Disease Treatments and Financial Decision-Making.Healthcare (Basel, Switzerland) · 2025Review
- EAAT2 Activation Regulates Glutamate Excitotoxicity and Reduces Impulsivity in a Rodent Model of Parkinson's Disease.Molecular neurobiology · 2025Article
- Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management.CNS drugs · 2024Review
- Anger, agency, risk and action: a neurobehavioral model with proof-of-concept in healthy young adults.Frontiers in psychology · 2023Article
- Dopamine-induced changes to thalamic GABA concentration in impulsive Parkinson disease patients.NPJ Parkinson's disease · 2022Article
- A Bayesian method for measuring risk propensity in the Balloon Analogue Risk Task.Behavior research methods · 2022Article
- Neurophysiological Correlates of Trait Impulsivity in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021Article
- Investigating the effects of genetic risk of schizophrenia on behavioural traits.NPJ schizophrenia · 2021Article
- Self-reported rates of impulsivity in Parkinson's Disease.Annals of clinical and translational neurology · 2020Article
- Evolution of impulsive-compulsive behaviors and cognition in Parkinson's disease.Journal of neurology · 2020Article
- Iowa Gambling Task Performance in Parkinson Disease Patients with Impulse Control Disorders.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2019Article
- Dopaminergic influences on risk preferences of Parkinson's disease patients.Cognitive, affective & behavioral neuroscience · 2019Article
- Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review.Frontiers in neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Risk-taking behavior is characterized by pursuit of reward in spite of potential negative consequences. Dopamine neurotransmission along the mesocorticolimbic pathway is a potential modulator of risk behavior. In patients with Parkinson's disease (PD), impulse control disorder (ICD) can result from dopaminergic medication use, particularly dopamine agonists (DAA). Behaviors associated with ICD include hypersexuality as well as compulsive gambling, shopping, and eating, and these behaviors are potentially linked to alterations to risk processing. Using the Balloon Analogue Risk Task, we assessed the role of agonist therapy on risk-taking behavior in PD patients with (n = 22) and without (n = 19) active ICD symptoms. Patients performed the task both "on" and "off" DAA. DAA increased risk-taking in PD patients with active ICD symptoms, but it did not affect risk behavior of PD controls. DAA dose was also important in explaining risk behavior. Both groups similarly reduced their risk-taking in high compared to low risk conditions and following the occurrence of a negative consequence, suggesting that ICD patients do not necessarily differ in their abilities to process and adjust to some aspects of negative consequences. Our findings suggest dopaminergic augmentation of risk-taking behavior as a potential contributing mechanism for the emergence of ICD in PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.